TEAM

Leadership

Rahul Kakkar, MD

President & Chief Executive Officer​

Matt Barrows

Chief of Quality & Technical Operations

Jonathan (John) Finn, PhD

Chief Scientific Officer

Edward Freedman, JD

Chief Operating Officer

Diane Wong

Chief People Officer

Pauline McGowan

SVP, Finance

Michelle Avery, PhD

SVP, Corporate Affairs

Board

Omar Abudayyeh, PhD

Co-Founder

Omar is a Lead Investigator at Brigham and Women’s Hospital, and our Co-Founder. He shares a board seat with Jonathan Gootenberg.​

Jorge Conde

a16z

Jorge is a General Partner at Andreessen Horowitz where he leads investments at the cross section of biology, computer science and engineering.

Alan Crane

Polaris Partners

Alan is an entrepreneur partner at Polaris Partners, focusing on building and investing in healthcare companies.

Dan Curran, MD

Independent

Dan is currently consulting for biotechnology and pharmaceutical companies. He was previously Head of Rare Genetics and Hematology at Takeda.

Jonathan Gootenberg, PhD

Co-Founder

Jonathan is a Lead Investigator at Beth Israel Deaconess Medical Center, and our Co-Founder. He shares a board seat with Omar Abudayyeh.​

Dan Lynch

Chairman, GV

Dan is an Executive Venture Partner at GV, where he advises and served as a member of the board for a number of biopharmaceutical companies.

Rahul Kakkar, MD

President & CEO

Rahul serves as our President and Chief Executive Officer.

Key Investors

Collaborators

We believe programmable genomic integration has significant opportunity across therapeutic areas and welcome collaborations that will enable the development of our technology for patients in need. Contact us: BD@tome.bio

                                        Contact     100 Talcott Ave., Watertown, MA 02472     hello@tome.bio

Views: 1405

Rahul Kakkar, MD
President & Chief Executive Officer​

Rahul is a biotech executive and physician-scientist, founding and building biotechnology companies as well as working as a practicing physician. He also serves as an Entrepreneur Partner at Polaris Partners. Most recently, Rahul was Chief Executive Officer at Pandion Therapeutics, a company focused on therapeutics for autoimmune and inflammatory diseases, which he led from Series A through its initial public offering and ultimate acquisition by Merck for $1.85B. Prior to joining Pandion, Rahul founded Corvidia Therapeutics, a precision cardiovascular company, where he served as Chief Medical Officer and Chief Strategy Officer. Corvidia Therapeutics was acquired by Novo Nordisk for $2.1B. Prior to Corvidia, Rahul served as a director in the Emerging Innovations Unit at AstraZeneca. Rahul practices cardiovascular medicine at the Brigham and Women’s Hospital in Boston and is a lecturer in medicine at Harvard Medical School. Rahul received his BA from Tufts University and MD from the Tufts University School of Medicine.

Matt Barrows

Chief of Quality & Technical Operations

Matt brings over 20 years of senior leadership in chemistry, manufacturing and controls. He was most recently Executive Director, Commercial Manufacturing at Moderna Therapeutics, where he led the manufacturing scale-up of Spikevax, Moderna’s COVID-19 vaccine and Moderna’s Personalized Cancer Vaccine scale-out and production. Prior to that, Matt served as Upstream Manufacturing Lead & Head of Operational Readiness at Alexion Pharmaceuticals and held leadership roles at Genzyme/Sanofi in Manufacturing, Process/Automation Engineering and Consent Decree Remediation. He received his MBA from Northeastern University and BS in Biotechnology from Worcester Polytechnic Institute.

Jonathan (John) Finn, PhD
Chief Scientific Officer
John brings over 20 years of gene therapy experience with a focus on genome editing and delivery technologies. He was most recently Vice President of Discovery Research at Codiak Biosciences, where he led the development of a new class of therapeutics based on engineered exosomes. Prior to Codiak, John was Executive Director of Platform Biology and Liver Discovery at Intellia Therapeutics, where he was responsible for the development of viral and non-viral delivery systems and demonstrated the first in vivo systemic administration of CRISPR-based therapeutics. Previously, John served as Director of Research at Arthrogen, developing novel AAV and exosome-based therapeutics. He has served as an American Society of Gene and Cell Therapy (ASGCT) Committee Member for multiple committees, including Nanoagents and Synthetic Formulations; Genome Editing; Immune responses; and Metabolic and Inherited Disease. John trained with Pieter Cullis and Ian MacLachlan and received his PhD in Biochemistry and Molecular Biology from the University of British Columbia and BS in Molecular Biology and Genetics from the University of Guelph. He completed post-doctoral programs in Immunology and Vaccine research at McMaster University (Jonathan Bramson lab) and Hematology and Gene Therapy at the Children’s Hospital of Philadelphia (Kathy High Lab).

Edward Freedman, JD

Chief Operating Officer

Edward brings more than two decades of financial, legal and operational leadership expertise to his role, specializing in early-stage biotech companies. He also serves as founder and principal at his firm, Freedman Advisors, Chief Operating Officer at Seismic Therapeutic and Chief Financial Officer at Faze Medicines. Previously, Edward served as Chief Operating Officer at Pandion Therapeutics, Chief Financial Officer at KSQ Therapeutics, Chief Financial Officer at Xtuit Pharmaceuticals, Chief Financial Officer and General Counsel at Oasys Water, Vice President of Operations and Finance and General Counsel at Ensemble Therapeutics, and General Counsel at Flagship Ventures. Edward received his JD from Boston College Law School and his BSBA in accounting from Boston University.

Diane Wong

Chief People Officer

Diane brings over 15 years of HR leadership experience from both entrepreneurial and established biopharmaceutical organizations. She joins us from Constellation Pharmaceuticals where she was VP of Human Resources, preparing the organization for rapid growth. Prior to that, she held HR business partner and talent management roles at Novartis and Biogen, supporting several commercial organization and G&A functions. Diane received her BS in psychology from the University of Massachusetts, Amherst.

Pauline McGowan

SVP, Finance

Pauline has more than 25 years of financial planning, accounting and operational experience in the life sciences industry. Most recently, Pauline served as SVP of Finance at Cygnal Therapeutics, where she built and led an operations team to provide finance, human resources, information technology and public relations support. Prior to that, Pauline was the Head of Finance at Gingko Bioworks during a period of rapid growth, including a $275M Series D financing and $100M joint venture with Bayer. Pauline also served as VP of Finance at Concert Pharmaceuticals, where she built the finance function and managed its governance and SEC compliance through S-1 filing and IPO in 2014. She began her professional career at Pricewaterhouse Coopers LLP. Pauline received her BS in business administration from Villanova University and is a Certified Public Accountant in Massachusetts.

Michelle Avery, PhD

SVP, Corporate Affairs

Michelle brings over a decade of experience in corporate communications, investor relations and public relations. She most recently served as Sr. Director, IR, at Pandion Therapeutics, which was acquired by Merk for $1.85 billion in April 2021. Previously, Michelle held roles of increasing responsibility at Summit Therapeutics, where she oversaw US investor relations and corporate communications and global patient engagement. She began her career at MacDougall Biomedical Communications, where she served a variety of public and private clients. Michelle holds a PhD in neuroscience from the University of Massachusetts Chan Medical School and a BA in neuroscience and dance from Skidmore College.

Omar Abudayyeh, PhD
Co-Founder

Omar Abudayyeh is a Lead Investigator at Brigham and Women’s Hospital where he directs a lab developing next-generation cell profiling, molecular diagnostics, gene editing, gene delivery, and synthetic biology technologies. These tools, including the popular gene editing system CRISPR, allow for unprecedented manipulation and profiling of cellular states with multiple applications in basic science and for programmable therapeutics and diagnostics. Dr. Abudayyeh also applies many of these tools towards answering fundamental questions about the effect of aging on the brain and other organs with the goal of developing regenerative therapeutics.

He was previously a McGovern Institute Fellow at MIT. Prior to that, he was at Harvard Medical School and MIT as a graduate student in Feng Zhang’s lab at the Broad Institute, where he earned a Ph.D. researching novel CRISPR enzymes for genome editing, therapeutics, and diagnostics. He is a pioneer in the gene editing space as an inventor on dozens of patents and patent applications relating to gene editing and diagnostic innovations, as well as over 25,000 citations on over 40 peer-reviewed articles in journals like Nature, Science, and Cell. He is also co-founder of Sherlock Biosciences and Proof Diagnostics, which are commercializing CRISPR-based diagnostics for healthcare and at-home testing, as well as numerous other stealth starts ups in the gene therapy space, including Tome Biosciences and Doppler Bio. Dr. Abudayyeh has been recognized as Technology Review Innovators Under 35, Bloomberg New Economy Catalyst, Endpoints 20 under 40 Next Generation of Biotech Leaders, 2022 Termeer Scholar, 2018 Forbes 30 under 30, Business Insider 30 under 30, a 2018 TEDMED Hive honoree, and a 2013 Paul and Daisy Soros Fellow. Dr. Abudayyeh graduated from MIT in 2012 with a B.S. in mechanical engineering and biological engineering, where he was a Henry Ford II Scholar and a Barry M. Goldwater Scholar. He also spent two years studying towards an MD at Harvard Medical School.

Jonathan Gootenberg, PhD
Co-Founder

Jonathan Gootenberg draws from fundamental biological insights to engineer new molecular tools. These technologies, including CRISPR-mediated genome and transcriptome perturbation and non-destructive cellular sensing, allow for unprecedented manipulation and profiling of cellular states in the body, and have multiple applications in basic science, diagnostics, and therapeutics. These technologies have been translated into multiple biotechnology companies, including 5 companies that Dr. Gootenberg has co-founded.

Dr. Gootenberg earned his bachelor’s degree in mathematics and biological engineering at MIT. He received his PhD in systems biology from Harvard University, during which he conducted research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute of MIT and Harvard. He was one of the first members of the McGovern Institute Fellows program, which supports the transition to independent research for exceptional recent PhD graduates. Jonathan is currently a Lead Investigator at Beth Israel Deaconess Medical Center.He has been recognized with awards including Forbes 30 under 30, Technology Review 35 under 35, Business Insider 30 and under, Endpoints 20 under 40, and as an inaugural Termeer Foundation scholar.